Results

Total Results: 744 records

Showing results for "calculate".

301. Cad-Women-Diagnosis Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cad-women-diagnosis_executive.pdf
     June 01, 2012 - 1 Comparative Effectiveness Review Number 58 Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women Executive Summary Background Cardiovascular disease is the leading cause of mortality for women in the United States.1 Coronary heart disease— which includes coronary artery (or atheroscl…

302. Bladder-Cancer-Non-Muscle-Invasive Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/bladder-cancer-non-muscle-invasive_executive.pdf
     October 01, 2015 - 1 Comparative Effectiveness Review Number 153 Emerging Approaches to Diagnosis and Treatment of Non–Muscle-Invasive Bladder Cancer Executive Summary Background Bladder cancer is the 4th most commonly diagnosed cancer in men and the 10th most commonly diagnosed cancer in women in the United States.1 The Ameri…

303. Trauma Informed Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/trauma-informed-care-protocol.pdf
     April 19, 2023 - We will calculate risk ratios (RR) and absolute risk differences (RD) with the corresponding 95 percent

304. Multidisciplinary Rehabilitation Programs for Moderate to Severe Traumatic Brain Injury in Adults: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/traumatic-brain-injury-rehabilitation-future_research.pdf
     January 01, 2013 - Multidisciplinary Rehabilitation Programs for Moderate to Severe Traumatic Brain Injury in Adults: Future Research Needs Future Research Needs Paper Number 36 Multidisciplinary Rehabilitation Programs for Moderate to Severe Traumatic Brain Injury in Adults: Future Research Needs Future Research Needs Paper N…

305. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/acs-pci-adjunctive-devices_executive.pdf
     December 01, 2011 - Layout 1 Background Coronary stents and adjunctive pharmacologic agents—including glycoprotein IIb/IIIa receptor inhibitors and thienopyridines—have improved the efficacy of percutaneous coronary intervention (PCI).1,2 However, dislodgement of atherothrombotic material from coronary lesions during PCI can result in …

306. GRADING THE STRENGTH OF A BODY OF EVIDENCE (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-grading-evidence_methods.pdf
     November 01, 2013 - challenging when 20 some studies in the evidence base do not report (or reviewers cannot independently calculate

307. Stroke Prevention in Atr ial Fibr illation Patients: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/stroke-afib-update_research-protocol-amended.pdf
     October 27, 2017 - ranges from 0 to 6, with increasing scores corresponding to increasing stroke risk, and is easy to calculate … ranges from 0 to 9, with increasing scores corresponding to increasing stroke risk, and is easy to calculate

308. Smoking-Pregnancy-Infants Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/smoking-pregnancy-infants_executive.pdf
     February 01, 2014 - The meta-analysis presented in this review allowed us to calculate the posterior probability that specific

309. Dementia-Agitation-Aggression Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/dementia-agitation-aggression_research-protocol.pdf
     November 13, 2014 - We will calculate risk ratios (RR) and absolute risk differences (RD) with the corresponding 95 percent

310. Nutrition as Prevention for Improved Cancer Outcomes (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/improved-cancer-outcomes-protocol_0.pdf
     December 01, 2021 - When pooling is possible, we will synthesize data using random effects models and will calculate risk

311. Cer-250-Cannabis-2025-Surv-Rep-Update-Tables-E1-4 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-tables-e1-4.xlsx
     January 01, 2025 - E-1. Can. Study Characteristics Table E-1. Cannabis RCTs study characteristics PMID Author, Year Study Design Crossover Design Enriched Enrollment Randomized Withdrawal Design Setting Pain Population Pain Condition Prior Cannabis Exposure Age Measure (Mean, Median) Age, Years Female % Race, White % Race, Black % Race…

312. Diagnosis of Celiac Disease: Current State of the Evidence (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/celiac-disease_clinician.pdf
     July 01, 2016 - Diagnosis of Celiac Disease: Current State of the Evidence Diagnosis of Celiac Disease: Current State of the Evidence Background Focus of This Summary This is a summary of a systematic review evaluating the evidence regarding the comparative accuracy (the balance of sensitivity and specificity) and possible adv…

313. Transparency of Reporting Requirements: Strategies to Improve Mental Health Care for Children and Adolescents (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/transparency-mental-health_research-protocol.pdf
     September 01, 2016 - Transparency of Reporting Requirements: Strategies to Improve Mental Health Care for Children and Adolescents Source: www.effectivehealthcare.ahrq.gov Published online: September 1, 2016 Evidence-based Practice Center Methodology Report Protocol Project Title: Transparency of Reporting Requirements Rep…

314. Gastric-Cancers-Supplementary-App-I (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/gastric-cancers-supplementary-app-i.xlsx
     January 01, 2019 - ICEMAN - Primary studies RefID Study name State a single candidate effect modifier Was the effect modifier measured before or at randomization/assignment? State a single outcome and time-point of interest State a single effect measure 1: Was the direction of the effect modification correctly hypothesized a priori? 1: …

315. Disposition of Comments Report for Biologic and Nonbiologic Systemic Agents and Phottherapy for Treatment of Chronic Plaque Psoriasis (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_disposition-comments.pdf
     November 27, 2012 - We presented all data in the form which it was reported for all studies and did not calculate any statistics

316. Febrile-Infants-Diagnosis-Management Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/febrile-infants-diagnosis-management_executive.pdf
     March 01, 2012 - Moreover, we attempted to calculate the test accuracy characteristics from raw data for the different

317. FRN 22: Future Research Needs for Strategies To Reduce Cesarean Birth in Low-Risk Women (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/cesarean-birth_research.pdf
     January 01, 2020 - FRN 22: Future Research Needs for Strategies To Reduce Cesarean Birth in Low-Risk Women Future Research Needs Paper Number 22 Future Research Needs for Strategies To Reduce Cesarean Birth in Low- Risk Women Future Research Needs Paper Number 22 Future Research Needs for Strategies To Reduce Cesarean Birth …

318. Asthma-Immunotherapy-2010 Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/asthma-immunotherapy-2010_research-protocol.pdf
     January 01, 2010 - Measures of Treatment Effect We will calculate summary risk ratios or odds ratios as appropriate … We will verify normality of continuous outcomes and calculate mean differences; standardized mean differences

319. App-D-Opioid-Chronic-Pain-Surveillance-Report-3 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-3.xlsx
     September 30, 2015 - Appendix Table D-1. RCTs Table D-1. Randomized controlled trials Author, Year Study Design Duration Setting Country Eligibility Criteria Interventions Sample Characteristics Screened Eligible Randomized Analyzed Results Adverse Events and Withdrawals Due to Adverse Events Sponsor Quality Hruschak, 2021 RCT Duration:…

320. PHARMACO-EPIDEMIOLOGIC METHODS FOR A STUDY OF (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotic-medicine-mortality-elderly_research.pdf
     March 01, 2009 - PHARMACO-EPIDEMIOLOGIC METHODS FOR A STUDY OF The DEcIDE (Developing Evidence to Inform Decisions about Effectiveness) network is part of AHRQ’s Effective Health Care program. It is a collaborative network of research centers that support the rapid development of new scientific information and analyti…